10 at 10: These ASX stocks have grabbed the most attention this morning
News
News
Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data.
It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.
The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has commenced trading.
Stocks highlighted in yellow have made market-moving announcements (click headings to sort).
Code | Company | Price | % | Volume |
---|---|---|---|---|
DNA | Donaco International | 0.077 | 54 | 3012620 |
CLZ | Classic Min Ltd | 0.0015 | 50 | 14250000 |
TIG | Tigers Realm Coal | 0.015 | 45 | 1120780 |
BIQ | Buildingiq, Inc | 0.014 | 27 | 5566824 |
BDM | Burgundy D Mines Ltd | 0.18 | 20 | 486204 |
TSC | Twenty Seven Co. Ltd | 0.006 | 20 | 1186666 |
VIC | Victory Mines Ltd | 0.003 | 20 | 228365 |
GML | Gateway Mining | 0.033 | 18 | 8608566 |
AMD | Arrow Minerals | 0.007 | 17 | 830714 |
GTG | Genetic Technologies | 0.008 | 14 | 59000 |
Todays biggest mover was casino operator Donaco International (ASX:DNA) which reported trading conditions had improved in recent weeks as the impacts of COVID-19 subsided.
In Gold, Gateway Mining (ASX:GML) climbed off the back of an exploration update while Twenty Seven Co (ASX:TSC) won approval for a new drilling campaign.
Tigers Realm Coal (ASX:TIG) rose after completing a capital raising.
Code | Company | Price | % | Volume |
---|---|---|---|---|
MLS | Metals Australia | 0.001 | -33 | 700 |
EN1 | Engage:Bdr Limited | 0.005 | -17 | 311643 |
PNX | PNX Metals Limited | 0.006 | -14 | 376818 |
ICQ | Icar Asia Ltd | 0.325 | -13 | 503427 |
MSB | Mesoblast | 2.16 | -42 | 7745234 |
BFC | Beston Global Ltd | 0.077 | -11 | 1400493 |
MMJ | MMJ Group Hlds Ltd | 0.125 | -11 | 672005 |
MRG | Murray River Grp | 0.009 | -10 | 100000 |
NRX | Noronex Limited | 0.105 | -9 | 35185 |
CPH | Creso Pharma Ltd | 0.165 | -8 | 8498856 |
Mesoblast (ASX:MSB) fell again after an update on its clinical trial against ARDS.